Shanghai Wentai Bio Technology

Shanghai Wentai Bio Technology is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the research and development of innovative vaccines. The company leverages two primary technology platforms: a structure-based recombinant protein platform and a proprietary mRNA delivery system. Its lead candidate, WT-001, is a recombinant protein vaccine for COVID-19 that has successfully entered Phase 2 clinical trials. Wentai Bio focuses on addressing global health challenges through the development of next-generation biological products for infectious diseases, including seasonal influenza and emerging viral threats. The company integrates advanced molecular design with large-scale manufacturing capabilities to ensure the rapid deployment of high-quality vaccines.